TNON

+ Watchlist + Portfolio

Tenon Medical, Inc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.04
52-Week Range: $2.40 – $50.40
Market Cap: $5.94M
P/E (TTM): —
EPS (TTM): -44.86
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -551.19%
Return on Assets: -71.98%
Gross Margin: 66.81%
Operating Margin: -262.24%
Profit Margin: -257.85%
Current Ratio: 0.58
Debt/Equity: —
Total Debt: $5.68M
Free Cash Flow: $-6.12M
Revenue Growth: 126.80%
Earnings Growth: —
Enterprise Value: $9.54M

TNON Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$691.00K	$2.93M	$3.28M	$3.94M
Cost of Revenue	$1.33M	$1.69M	$1.57M	$1.59M
Gross Profit	-$641.00K	$1.24M	$1.71M	$2.36M
Research & Development	$2.83M	$3.16M	$2.60M	$2.15M
Selling, General & Admin	$15.26M	$13.80M	$12.87M	$13.00M
Operating Expenses	$18.08M	$16.97M	$15.48M	$15.15M
Operating Income	-$18.73M	-$15.73M	-$13.77M	-$12.79M
EBITDA	-$18.27M	-$15.13M	-$12.98M	-$12.03M
Pretax Income	-$18.92M	-$15.58M	-$13.67M	-$12.56M
Net Income	-$18.92M	-$15.58M	-$13.67M	-$12.56M
Diluted EPS	-6613.60	-2405.20	-394.10	-59.50
Diluted Shares	2860	6478	34685	210971

TNON Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$2.13M	$2.43M	$6.54M	$3.76M
Receivables	$228.00K	$518.00K	$863.00K	$1.70M
Inventory	$415.00K	$554.00K	$606.00K	$1.05M
Current Assets	$9.35M	$3.89M	$8.21M	$6.77M
Total Assets	$11.09M	$6.34M	$9.84M	$10.76M
Current Liabilities	$2.53M	$3.14M	$1.87M	$3.21M
Total Debt	$911.00K	$1.86M	$428.00K	$141.00K
Total Liabilities	$4.84M	$5.57M	$3.87M	$5.72M
Retained Earnings	-$39.49M	-$55.07M	-$68.75M	-$81.30M
Shareholders' Equity	$6.25M	$778.00K	$5.97M	$5.04M
Working Capital	$6.82M	$749.00K	$6.34M	$3.56M

TNON Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$12.03M	-$12.18M	-$9.88M	-$10.74M
Capital Expenditure	-$847.00K	-$361.00K	-$186.00K	-$273.00K
Free Cash Flow	-$12.87M	-$12.54M	-$10.06M	-$11.02M
Depreciation & Amortisation	$289.00K	$426.00K	$655.00K	$530.00K
Stock-Based Compensation	$2.90M	$4.14M	$3.85M	$1.69M
Investing Cash Flow	-$2.88M	$6.14M	-$186.00K	-$1.02M
Financing Cash Flow	$14.11M	$6.30M	$14.13M	$8.99M
Net Change in Cash	-$795.00K	$261.00K	$4.06M	-$2.78M

TNON Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$726.00K	$564.00K	$1.17M	$1.48M	$1.38M	$1.28M
Cost of Revenue	$403.00K	$319.00K	$400.00K	$464.00K	$434.00K	$465.00K
Gross Profit	$323.00K	$245.00K	$773.00K	$1.02M	$945.00K	$814.00K
Research & Development	$691.00K	$503.00K	$428.00K	$527.00K	$662.00K	$768.00K
Selling, General & Admin	$3.31M	$2.60M	$3.74M	$3.36M	$3.56M	$3.40M
Operating Expenses	$4.00M	$3.10M	$4.17M	$3.88M	$4.22M	$4.17M
Operating Income	-$3.68M	-$2.86M	-$3.39M	-$2.87M	-$3.28M	-$3.35M
EBITDA	-$3.51M	-$2.65M	-$3.19M	-$2.67M	-$3.15M	-$3.07M
Pretax Income	-$3.62M	-$2.77M	-$3.34M	-$2.83M	-$3.48M	-$4.05M
Net Income	-$3.62M	-$2.77M	-$3.34M	-$2.83M	-$3.48M	-$4.05M
Diluted EPS	-35.35	-12.76	-14.00	—	-10.85	-12.35
Diluted Shares	102771	216999	235714	—	321942	327999

TNON Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$10.31M	$7.85M	$3.44M	$3.76M	$4.61M	$1.68M
Receivables	$886.00K	$770.00K	$1.31M	$1.70M	$1.97M	$1.95M
Inventory	$607.00K	$688.00K	$1.36M	$1.05M	$806.00K	$783.00K
Current Assets	$11.99M	$9.88M	$6.54M	$6.77M	$7.62M	$4.81M
Total Assets	$13.39M	$11.11M	$10.37M	$10.76M	$12.84M	$9.92M
Current Liabilities	$2.19M	$2.56M	$3.04M	$3.21M	$7.41M	$8.30M
Total Debt	$360.00K	$290.00K	$216.00K	$141.00K	$4.88M	$5.68M
Total Liabilities	$4.02M	$4.40M	$5.57M	$5.72M	$10.94M	$11.66M
Retained Earnings	-$72.36M	-$75.13M	-$78.47M	-$81.30M	-$84.78M	-$88.83M
Shareholders' Equity	$9.38M	$6.71M	$4.80M	$5.04M	$1.90M	-$1.74M
Working Capital	$9.79M	$7.32M	$3.50M	$3.56M	$215.00K	-$3.50M
Net Debt	—	—	—	—	—	$2.65M

TNON Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$2.48M	-$2.21M	-$3.82M	-$2.22M	-$2.96M	-$2.76M
Capital Expenditure	—	—	—	-$192.00K	-$56.00K	-$172.00K
Free Cash Flow	-$2.48M	-$2.41M	-$3.71M	-$2.42M	-$3.02M	-$2.93M
Depreciation & Amortisation	$107.00K	$114.00K	$145.00K	$164.00K	$153.00K	$128.00K
Stock-Based Compensation	$872.00K	$417.00K	$58.00K	$344.00K	$331.00K	$412.00K
Investing Cash Flow	$0.00	-$192.00K	-$639.00K	-$192.00K	-$56.00K	-$172.00K
Financing Cash Flow	$6.26M	-$59.00K	$59.00K	$2.73M	$3.87M	$0.00
Net Change in Cash	$3.78M	-$2.46M	-$4.40M	$314.00K	$851.00K	-$2.93M

Market Snapshot

About

Tenon Medical is a medical device company focused on developing and commercializing minimally invasive solutions for spine surgery. The company has developed the CATAMARAN Sacroiliac Joint Fusion System, designed to treat sacroiliac joint dysfunction with improved clinical outcomes. Tenon Medical aims to provide surgeons with innovative tools that enhance patient recovery and reduce procedural complexity.